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We aimed to determine the prognostic significance of pretreatment plasma fibrinigen in
patients with oral and oropharyngeal squamous cell carcinoma (OOSCC).
Methods
A cohort of 183 patients with locally advancedOOSCC receiving preoperative chemora-
diotherapy was retrospectively examined. Using ROC curve analysis, a pretreatment plasma
fibrinogen cutoff value of 447mg/dL was determined. The primary endpoints were overall sur-
vival and recurrence-free survival. A secondary endpoint was to determine whether pretreat-
ment plasma fibrinogen could predict treatment response to neoadjuvant chemoradiotherapy.
Cox regression models and Kaplan–Meier curves were used for survival analyses.
Results
Seventy-one patients had an elevated pretreatment plasma fibrinogen (fibrinogen >447mg/
dL). Patients with high fibrinogen showed significantly higher pathologic stages after neoad-
juvant treatment than those with low fibrinogen (p = 0.037). In univariate analysis, elevated
fibrinogen was associated with poor overall survival (p = 0.005) and recurrence-free survival
(p = 0.008) Multivariate analysis revealed that elevated fibrinogen remained an independent
risk factor for death (hazard ratio 1.78, 95% CI 1.09–2.90, p = 0.021) and relapse (hazard
ratio 1.78, 95% CI 1.11–2.86, p = 0.016).
Conclusion
Elevated pretreatment plasma fibrinogen is associated with lack of response to neoadjuvant
chemoradiotherapy and reduced OS and RFS in patients with OOSCC. Thus, plasma
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fibrinogen may emerge as a novel prognostic indicator and a potential therapeutic target in
OOSCC.
Introduction
Oral and oropharyngeal squamous cell carcinoma (OOSCC) is the sixth leading cancer and a
major cause of morbidity and mortality worldwide [1]. Despite substantial treatment advances,
the overall survival of patients with OOSCC continues to hover around 50% at 5 years, primar-
ily because patients develop locoregional recurrence and/or metastatic disease [2]. In recent
years, cancer research has been concentrated on the characterization of novel markers, which
ideally should have the potential to select patients who will benefit from specific treatment and
identify those at high risk for disease recurrence and death [3].
There is strong evidence suggesting that plasma fibrinogen, an acute phase glycoprotein that
is associated with the maintenance of hemostasis, is a central factor in both inflammation and
cancer development [4]. The results of numerous clinical studies have shown that elevated pre-
treatment plasma fibrinogen levels are associated with worse survival in a diversity of malignan-
cies, including lung, gastroesophageal, colorectal, ovarian, pancreatic, and hepatobiliary cancer
[5]. Evidence for the use of plasma fibrinogen as predictor of clinical outcome in patients with
head and neck cancer is limited [6–8]. Given this background, the purpose of this study was to
assess the value of pretreatment plasma fibrinogen in predicting overall survival (OS) and recur-
rence-free survival (RFS) in patients with locally advanced OOSCC who received preoperative
chemoradiotherapy. We hypothesized that elevated pretreatment plasma fibrinogen represents a
marker of worse survival in patients with oral and oropharyngeal cancer.
Patients and Methods
Study Population and Treatment
The study population comprised patients with primary locally advanced OOSCC who were
treated with curative-intent neoadjuvant chemoradiation (CRT) followed by radical cancer
surgery at the Departments of Radiotherapy and Cranio-Maxillofacial and Oral Surgery, at the
Medical University of Vienna, between 2000 and 2011. Patients suitable for inclusion in this
study had to meet the following criteria: (i) biopsy-confirmed primary OOSCC, (ii) no previous
treatment for OOSCC, (iii) disease Tumour Node Metastasis (TNM) stages III and IV, (iv)
World Health Organization (WHO) performance status and laboratory parameters allowing
chemotherapy and surgery, (v) clear resection margins (R0), and (vi) available complete blood
counts, including plasma fibrinogen, obtained up to 1 week prior to neoadjuvant chemora-
diotherapy (pretreatment). At the time of sampling, no patient showed any sign of active
inflammation or infection. Exclusion criteria were: (i) staging with distant metastatic disease
(M1), (ii) previous history of squamous cell carcinomas of the head and neck, and (iii) coagula-
tion disorders. All patients underwent neoadjuvant CRT consisting of mitomycin C (15 mg/
m2, i.v. bolus injection on day 1) administered with 5-fluorouracil (750 mg/m2/day, continuous
infusions on days 1–5) and concurrent radiotherapy over 5 weeks up to a total dose of 50 Gy
(25 fractions of 2 Gy per day). The surgical procedure was scheduled 4–8 weeks after the end of
radiotherapy. All patients received the same protocol of surgery consisting of radical resection
of the primary tumor, guided by pretreatment margins defined by ink tattoo, with a macro-
scopic safe margin of at least 1 cm and concurrent neck dissection according to pretreatment
lymph node status (neck dissection in levels I–III was performed for the clinically negative
neck (N0), and neck dissection in levels I–V for clinically positive neck lymph nodes (N+)).
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Patients were followed up on a regular basis (in 3-month intervals during the first 2 years and
then in 6-month intervals for the next 3 years) for a minimum of 5 years or until death.
For all eligible patients a database was generated using demographic, clinicopathological and
follow-up data that were extracted from the Vienna General Hospital Patient Information System
(AKIM) together with data obtained from surgical and pathologic charts. The clinical and patho-
logical tumor staging was determined according to the TNM classification of the International
Union Against Cancer (UICC). Pathological examination of the surgical specimens was per-
formed by means of an institutional protocol providing information on histological grade (WHO
classification criteria), extension of the primary tumor, lymph node status, perineural invasion,
and resection margins. The local Institutional Review Board (the Ethics Committee of the Medi-
cal University of Vienna and Vienna General Hospital) approved this retrospective cohort study.
Fibrinogen Measurement
As a part of the clinical routine, blood samples were obtained by peripheral venous puncture
after overnight fasting and complete blood counts including plasma fibrinogen levels were
measured 24 hours to 1 week prior to neoadjuvant treatment. Plasma fibrinogen was assessed
according to the Clauss method using clotting reagents from Diagnostica Stago (Asnieres sur
Seine, France) [9].
Statistical Methods
The primary endpoints of this study were: (i) OS defined as the time from surgery to death from
any cause or last follow-up, and (ii) RFS defined as the time from surgery to disease recurrence
(locoregional or distant recurrence), death without recurrence or last follow-up. A secondary end-
point was to determine whether pretreatment plasma fibrinogen could predict treatment response
to neoadjuvant CRT. Descriptive statistics were used to summarize the clinicopathological charac-
teristics of the study cohort. Assessed variables were age, sex, smoking, clinical T category, clinical
N category, tumor grade, post-treatment pathologic TNM stage (ypTNM), perineural invasion, as
well as pretreatment plasma fibrinogen. Receiver operating characteristic (ROC) curves for OS
and RFS prediction were constructed to estimate the optimal cutoff points for plasma fibrinogen.
The optimal cutoff value was determined as the point on the ROC curve that maximizes the You-
den Index. The area under the ROC curve (AUC) was used to calculate discrimination ability.
The associations between clinicopathological variables and pretreatment plasma fibrinogen were
assessed using either the chi-square test or the trend version of chi-square test, as appropriate.
Survival curves were generated by means of the Kaplan–Meier method, and the log-rank test was
used to evaluate survival differences between groups. Hazard ratios (HR) and 95% confidence
intervals (CI) were calculated using univariate and multivariate (backward method) Cox propor-
tional hazards regression models to analyze the effects of prognostic variables OS and RFS. Statis-
tical significance was defined as a two-sided p-value<0.05. Statistical analysis of data was
performed using the Statistical Package for the Social Sciences (SPSS1, version 21.0; IBMCorp.,
Armonk, NY) andMedCalc statistical software v12.2.1.0.
Results
Patients’ Characteristics
Patient clinical and pathological characteristics are shown in Table 1. A total of 183 patients
with locally advanced OOSCC who received neoadjuvant chemoradiation followed by surgery
met the eligibility criteria for this study. The mean baseline plasma fibrinogen level was
420.6mg/dL (standard deviation ± 111.2). Using ROC curve analysis, a pretreatment plasma
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fibrinogen cutoff value of 447mg/dL was determined for both OS (sensitivity = 52%; specific-
ity = 68%; corresponding AUC = 0.598; Fig 1A) and RFS (sensitivity = 49%; specificity = 68%;
corresponding AUC = 0.571; Fig 1B). Fibrinogen values equal to or below the obtained cutoff
point were considered low (n = 112/183 patients), while fibringen values above the cutoff point
were defined as high (n = 71/183 patients).
Pretreatment Plasma Fibrinogen Predicts Response to Neoadjuvant
CRT
Of 183 patients, 91 (50%) achieved pathologic complete tumor response after neoadjuvant
treatment (ypT0N0M0), determined by the absence of residual invasive cancer within both the
Table 1. Correlation between pretreatment plasma fibrinogen levels and clinicopathological parameters in 183 patients with oral and oropharyn-
geal cancer.
Pretreatment plasma fibrinogen (mg/dL)
Variable Patients n (%) Low fibrinogen (447) n (%) High fibrinogen (>447) n (%) pa
Total n of patients 183 (100) 112 (61) 71 (39)
Age 0.94
60 years 114 (62) 70 (62) 44 (62)
>60 years 69 (38) 42 (38) 27 (38)
Sex 0.17
Male 134 (73) 78 (70) 56 (79)
Female 49 (27) 34 (30) 15 (21)
Smoking 0.99
Current 152 (83) 93 (83) 59 (83)
Former or never 31 (17) 19 (17) 12 (17)
Clinical T-category 0.26
T1-T2 47 (26) 32 (29) 15 (21)
T3-T4 136 (74) 80 (71) 56 (79)
Clinical N-category 0.042
N0 31 (17) 24 (21) 7 (10)
N+ 152 (83) 88 (79) 64 (90)
Tumor grade 0.002
G1 20 (11) 16 (14) 4 (5)
G2 144 (79) 91 (81) 53 (75)
G3 19 (10) 5 (5) 14 (20)
ypTNM stage 0.037b
ypT0N0M0 91 (50) 62 (55) 29 (41)
ypT0N+M0 14 (8) 10 (9) 4 (6)
ypTNM I 43 (23) 22 (20) 21 (30)
ypTNM II 6 (3) 4 (4) 2 (3)
ypTNM III 11 (6) 6 (5) 5 (7)
ypTNM IV 18 (10) 8 (7) 10 (14)
Perineural invasion 0.85
No 164 (90) 100 (89) 64 (90)
Yes 19 (10) 12 (11) 7 (10)
aChi-square test unless otherwise specified.
bTrend version of chi-square test.
Abbreviations: G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated.
doi:10.1371/journal.pone.0158697.t001
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primary site and regional lymph nodes. Pretreatment plasma fibrinogen status (low vs. high)
was statistically significant associated with pathologic stage after neoadjuvant CRT (Table 1).
Patients with elevated fibrinogen (fibrinogen>447mg/dL) showed significantly higher patho-
logic stages after neoadjuvant treatment than those with low fibrinogen (fibrinogen447mg/
dL) (p = 0.037). Elevated plasma fibrinogen was statistically significant correlated with clinical
N+ category (p = 0.042) and higher tumor grade (p = 0.002), while no association between
fibrinogen and clinicopathological parameters, such as age, sex, smoking, clinical T-category,
and perineural invasion was found.
Pretreatment Plasma Fibrinogen Correlates with Overall Survival and
Recurrence-Free Survival
The median follow-up of the total study population was 3.7 years. During this period, 66 of 183
patients died (34%). The estimated 2-year and 5-year overall survival rates of all 183 patients
were 75.1% and 57.4%, respectively. The recurrence-free survival rate was 72.8% at 2 years and
54.5% at 5 years.
Kaplan–Meier curves revealed that patients with high pretreatment plasma fibrinogen had a
significantly shorter overall survival compared to patients with low fibrinogen (log-rank
p = 0.004) (Fig 2). The overall survival probability at 5 years was 43.1% for patients in the high
fibrinogen group and 66.2% for patients in the low fibrinogen group. Additionally, patients
with high fibrinogen had a significantly shorter recurrence-free survival than those with low
fibrinogen (log-rank p = 0.007) (Fig 3). The recurrence-free survival probability at 5 years was
39.4% for patients in the high fibrinogen group and 63.5% for patients in the low fibrinogen
group.
Univariate and multivariate analyses of prognostic factors for OS and RFS using Cox pro-
portional hazards regression models are presented in Table 2. In univariate analysis, patients
with elevated pretreatment plasma fibrinogen experienced a significantly shorter OS than
those with low fibrinigen (p = 0.005). Advanced ypTNM (p = 0.017) and positive perineural
invasion (p< 0.001) were also significantly associated with worse OS. A multivariate regres-
sion model confirmed that high plasma fibrinogen was independently associated with shorter
OS (HR 1.78, 95% CI 1.09–2.90, p = 0.021). In univariate analysis, elevated pretreatment
plasma fibrinogen (p = 0.008), advanced ypTNM (p = 0.004) and positive perineural invasion
(p< 0.001) were statistically significantly associated with worse RFS. In multivariate analysis
high plasma fibrinogen (HR 1.78, 95% CI 1.11–2.86, p = 0.016) remained independently associ-
ated with poor RFS.
Discussion
In this study, we analyze a cohort of patients with locally advanced OOSCC to provide evidence
on the prognostic value of pretreatment plasma fibrinogen. We show that high pretreatment
plasma fibrinogen is independently associated with worse long-term overall survival and recur-
rence-free survival in patients with OOSCC. Our study also demonstrates that patients with
elevated pretreatment plasma fibrinogen have a significantly worse treatment response to
neodjuvant chemradiotherapy compared to those with low fibrinogen. Taken together, our
findings indicate that pretreatment plasma fibrinogen may be a novel prognostic marker in
OOSCC.
Fig 1. Receiver operating characteristic curves for pretreatment plasma fibrinogen predicting overall
survival (A), and recurrence-free survival (B). Using ROC curve analysis, a pretreatment plasma
fibrinogen cutoff value of 447mg/dL was determined for both OS and RFS.
doi:10.1371/journal.pone.0158697.g001
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The molecular mechanisms underlying the correlation between high pretreatment plasma
fibrinogen and worse survival of patients with OOSCC have not been clarified yet. Neverthe-
less, numerous in vitro studies have shown that fibrinogen mediates cancer cell proliferation,
epithelial-to-mesenchymal transition (EMT), invasion, angiogenesis, and hematogenous
metastasis, and therefore plays an important role in cancer progression [10–12]. Experimental
studies have demonstrated that fibrinogen binding to secreted growth factors, such as members
of the transforming growth factor-b (TGF-b), platelet-derived growth factor (PDGF), vascular
Fig 2. Kaplan–Meier estimates of the probability of overall survival in 183 patients with locally advanced OOSCC according
to low and high pretreatment plasma fibrinogen.
doi:10.1371/journal.pone.0158697.g002
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endothelial growth factor (VEGF), and fibroblast growth factor (FGF) families, promotes
tumor cell proliferation, inhibition of apoptosis, angiogenesis, and metastasis [13]. It has been
shown that tumor cells have the ability to produce endogenous fibrinogen and that FGF-2
binding to fibrinogen induces endothelial cell proliferation, thus resulting in increased angio-
genesis [14, 15]. Recent research has revealed that fibrinogen acts as a bridge between integrins
on platelets and circulating tumor cells (CTCs), and thus increases platelet adhesion to tumor
cells [16]. In the presence of thrombin, fibrinogen converts into a compact fibrin matrix, which
Fig 3. Kaplan–Meier estimates of the probability of recurrence-free survival in 183 patients with locally advanced OOSCC
according to low and high pretreatment plasma fibrinogen.
doi:10.1371/journal.pone.0158697.g003
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in combination with platelets forms a shielding cover around CTCs that protects them from
natural killer cell-mediated elimination [17].
It is generally acknowledged that cross-talk exists between coagulation, the inflammatory
response, and cancer progression [4, 18]. In the tumor microenvironment, fibrinogen mediates
leukocyte adhesion to endothelial cells and production of the pro-inflammatory cytokines in
peripheral blood mononuclear cells [19, 20]. Recent research has shown that fibrinogen-leuko-
cyte integrin receptor aMb2 interactions induce a fibrinogen-dependent inflammatory
response, which has a substantial effect on the pathogenesis and progression of cancer [10]. In
our study, the observed adverse effects of elevated pretreatment plasma fibrinogen on OS and
RFS of patients with OOSCC may reflect the substantial role of fibrinogen in an inflammatory
tumor microenvironment that favors tumor development.
A recent systematic review and meta-analysis provided strong evidence that an elevated pre-
treatment plasma fibrinogen is an independent predictor of worse OS and RFS in a wide variety
of malignancies, including lung, colorectal, renal, ovarian, cervical, endometrial, and head and
neck cancers [5]. In accordance with this meta-analysis, our study highlights the independent
prognostic effect of pretreatment plasma fibrinogen in patients with OOSCC. Our findings, if
validated in larger patient populations, have widespread clinical implications. Plasma fibrino-
gen is a universally available, routinely measured, and inexpensive biomarker, which can be
easily integrated into the clinical management of cancer patients. Furthermore, plasma fibrino-
gen could be simply applied in addition to established prognostic factors further improving
prognosis estimation, patient consulting, and treatment decision-making in patients with
OOSCC. Additionally, the evidence provided by the present study along with a convincing bio-
logical rationale associating fibrinogen with cancer progression suggest that adjunct treatments
lowering plasma fibrinogen levels and/or therapies targeting fibrinogen-dependent interactions
may hold promise for prolonging survival of patients with OOSCC.
This retrospective study is subject to several inherent limitations, such as the retrospective
design and the relatively small sample size. Furthermore, surgery followed by radiotherapy or
chemoradiotherapy is presently the mainstay of treatment for patients with locally advanced
OOSCC; nonetheless, some institutions using neoadjuvant CRT followed by surgery in the
management of patients with locally advanced OOSCC report an improved survival outcome
Table 2. Univariate andmultivariate analysis of prognostic factors for overall survival and recurrence-free survival in patients with oral and oro-
pharyngeal cancer.
Overall survival Recurrence-free survival
Univariate analysisb Multivariate analysisb Univariate analysisb Multivariate analysisb
Variablea HR 95% CI p HR 95% CI p HR 95% CI p HR 95% CI p
Age 1.15 0.69–1.92 0.58 1.15 0.71–1.88 0.56
Sex 0.73 0.41–1.30 0.28 0.81 0.46–1.39 0.44
Smoking 0.56 0.25–1.23 0.15 0.57 0.27–1.20 0.14
Clinical T-category 1.01 0.59–1.71 0.98 0.98 0.58–1.64 0.95
Clinical N-category 2.68 0.97–7.39 0.057 2.00 0.86–4.63 0.10
Tumor grade 1.33 0.77–2.30 0.30 1.36 0.81–2.28 0.23
ypTNM stage 0.91 0.84–0.98 0.017 0.89 0.83–0.96 0.004
Perineural invasion 3.34 1.71–6.52 <0.001 3.25 1.66–6.36 0.001 3.18 1.68–6.02 <0.001 2.93 1.55–5.54 0.001
Baseline plasma fibrinogen 2.00 1.23–3.25 0.005 1.78 1.09–2.90 0.021 1.89 1.18–3.02 0.008 1.78 1.11–2.86 0.016
aVariables were coded as described in Table 1. Baseline plasma fibrinogen was coded as low fibrinogen (447) and high fibrinogen (>447).
bCox proportional hazards regression models (backward method for multivariate analysis).
Abbreviations: OS, overall survival; RFS, recurrence-free survival; HR, hazard ratio; CI, confidence interval.
doi:10.1371/journal.pone.0158697.t002
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[21–23]. A unique aspect of the neoadjuvant treatment concept is that it offers the opportunity
to evaluate treatment response by determining pathologic stage after CRT and surgery. More-
over, the human papillomavirus (HPV) status was not considered in the group of patients with
oropharyngeal cancer, which may introduce a bias in the estimated effects. However, patient
groups with tumor localization either in the oropharynx or the oral cavity were similar with
respect to demographic characteristics (data not shown) and survival rates (the overall survival
probability at 3 years was 73% for patients with oropharyngeal cancer and 67% for patients
with oral cancer; log-rank p> 0.05). In addition, it was beyond the scope of this analysis to
investigate the mechanisms underlying the interaction between plasma fibrinogen, the systemic
inflammatory response and cancer progression. Nevertheless, evaluation of plasma fibrinogen
was achieved using clinicopathological and survival data from a homogeneous cohort of uni-
formly treated OOSCC patients with sufficient follow-up. The aforementioned limitations sug-
gest that further large-scale clinical studies are warranted to confirm our findings.
Conclusion
In conclusion, our study reveals the clinical significance of plasma fibrinogen in OOSCC. We
demonstrate that an elevated pretreatment plasma fibrinogen is associated with higher patho-
logic tumor stages after neoadjuvant treatment and reduced OS and RFS in patients with
OOSCC. Our results indicate that plasma fibrinogen may emerge as a novel prognostic marker
and a potential therapeutic target in OOSCC.
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